Méthodes innovantes pour améliorer la personnalisation des traitements pour les patients avec des sarcomes des tissus mous


Philip Wong

Centre hospitalier de l'Université de Montréal (CHUM)


Domaine : cancer

Programme chercheurs-boursiers cliniciens - Junior 1

Concours 2016-2017

Sarcomas are cancers that originate from the tissues that give support to the body, such as the bones, muscles, vessels and fat.  These cancers may occur at anywhere in the body at any age, from infancy to old age.  As 30-40% of young or old patients with sarcomas die within 5 years of diagnosis, the number of years of lives lost due to sarcoma is 2-3 times more than bowel, lung, prostate or breast cancers.

Sarcomas are very diverse.  They kill patients through distant metastasis and local recurrence.   A major aim of personalized medicine is to better identify patients in danger of relapsing and to treat them with medicine that is adapted to each patient's case.  This research program aims to 1) validate the ability of a prognostic microRNA signature in predicting a patient's risk of relapse from soft-tissue sarcoma and 2) develop a lab-on-a-chip biopsy assay that will indicate which drug-radiotherapy combination is best used to treat an individual's disease.

We will test the microRNA signature on 300 samples from patients who were previously treated for different aggressive and common sarcomas.    The lab-on-a-chip assay will first be developed, tested and optimized using laboratory sarcoma cells and mouse sarcomas.  Finally, we have proposed a proof-of-principle clinical trial to determine the feasibility of the methodology in clinical practice.

At the completion of this project, we would have defined the clinical utility of the microRNA signature in predicting the risk of relapse for individual patients with soft-tissue sarcomas.  Patients at high risk would be selected for more aggressive treatments that could be tailored according to the results from the lab-on-a-chip assay. The combined approach will potentially lead to the personalization of the medicine in the treatment of sarcomas.